Carroll P. Rising PSA after a radical treatment. Eur Urol 2001; 40 Suppl 2:9-16.Carroll P. Rising PSA after a radical treatment. Eur Urol 2001; 40 Suppl 2: 9-16.Carroll P. Rising PSA, after a radical treatment. Eur Urol. 2001;40:9–16....
A UCLA-led study has found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to as biochemical recurrence, do not necessarily improve a patient's long-term overall survival. The t...
For these reasons, we used TOAD trial data and criteria to define a similar retrospective cohort of men with rising PSA after definitive treatment of ... C Shin,DJ Herr,D Elliott,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2023年 Operative Management of a Complicated Intercostal...
The PSA test is used to monitor men after surgery or radiation therapy for prostate cancer to see if their cancer has recurred (come back). If a man’s PSA level begins to rise after prostate cancer treatment, it...
Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports theJournal of Urology. ...
Despite more than seven decades of knowledge about the effect of testosterone suppression on prostate cancer there is still a treatment dilemma of when to expose seemingly healthy men to the downsides of castration in the event of risin...
Similarly, PSADT 2.85 months derived by survival tree for PFS demonstrated better AUC compared to the AUC of median PSADT 5.26 months after 30 months of CRPC treatment. Patients with PSADT < 4.65 months had significantly shorter survival than those with PSADT ≥ 4.65 months. For PFS ...
To document current Australian management of asymptomatic prostate cancer patients with prostate-specific antigen (PSA) relapse after radical treatment or considered unsuitable for radical treatment. Four case scenarios—postprostatectomy PSA relapse, postradiotherapy (RT) with a slow or a rapidly rising ...
The reasons for opting out were multifactorial and at the discretion of the physician and patient who were both blind to the intervention arm but all had a rising PSA. Predetermined subgroup analysis A separate analysis of the cohort of men managed with AS (n ¼ 121) revealed that in the...
If you were high-risk before surgery, treatment will often be node radiation with 12 to 18 months of Lupron Depot. Your medical provider may suggest adding more powerful drugs like Zytiga, Xtandi, or Taxotere. Post-Radiation For a rising PSA after radiation, a popular approach is cryosurgery ...